Share on StockTwits

Stock analysts at Brean Capital increased their target price on shares of Celgene Corp. (NASDAQ:CELG) from $191.00 to $233.00 in a report issued on Tuesday, American Banking News reports. The firm currently has a “buy” rating on the stock. Brean Capital’s target price would indicate a potential upside of 39.49% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. Analysts at Barclays raised their price target on shares of Celgene Corp. from $173.00 to $182.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. Separately, analysts at Nomura initiated coverage on shares of Celgene Corp. in a research note to investors on Wednesday, January 8th. They set a “buy” rating on the stock. Finally, analysts at UBS AG downgraded shares of Celgene Corp. from a “hold” rating to a “sell” rating in a research note to investors on Tuesday, January 7th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and twenty have issued a buy rating to the company’s stock. Celgene Corp. presently has an average rating of “Buy” and a consensus target price of $166.40.

Shares of Celgene Corp. (NASDAQ:CELG) traded up 1.30% on Tuesday, hitting $167.04. 3,895,530 shares of the company’s stock traded hands. Celgene Corp. has a 1-year low of $96.30 and a 1-year high of $174.66. The stock has a 50-day moving average of $165.9 and a 200-day moving average of $150.. The company has a market cap of $68.832 billion and a price-to-earnings ratio of 47.48. Celgene Corp. also was the recipient of unusually large options trading activity on Monday. Traders bought 26,795 call options on the company. This is an increase of approximately 291% compared to the typical volume of 6,854 call options.

Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 24th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.02. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter in the previous year, the company posted $1.29 earnings per share. The company’s revenue for the quarter was up 18.0% on a year-over-year basis. Analysts expect that Celgene Corp. will post $6.00 EPS for the current fiscal year.

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.